Relmada Therapeutics, Inc. RLMD Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$58.88M+22.2% | -$57.39M+28.3% | -$56.17M+35.0% | -$67.81M+21.8% | -$75.71M+19.7% | ||
| $11.29M-55.7% | $13.91M-53.9% | $18.26M-45.2% | $22.6M-38.6% | $25.46M-37.5% | ||
| -$42.79M+24.7% | -$45.79M+11.5% | -$39.99M+24.8% | -$49.92M-3.6% | -$56.79M-17.8% | ||
| -$198.73M-449% | -$48.14M-193% | $40.14M-16.3% | $49.53M+38.8% | $56.86M+163% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Relmada Therapeutics, Inc. generate?
- Relmada Therapeutics, Inc. (RLMD) generated -$42.8M in operating cash flow over the trailing twelve months.
- What is Relmada Therapeutics, Inc.'s free cash flow?
- After $182.1M of capital expenditures, Relmada Therapeutics, Inc.'s free cash flow was -$209.9M over the trailing twelve months, down 116.5% year over year.
- Where does Relmada Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Relmada Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.